New Delhi: The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for AstraZeneca India Pharma Limited's proposal to update the prescribing information for Sodium Zirconium Cyclosilicate Powder for Oral Suspension (marketed as Lokelma) in 5 g and 10 g strengths.

The key changes in the proposed prescribing information are related to editorial changes in the posology and method of administration, special warnings and precautions for use, undesirable side effects, the list of adverse reactions and pharmacodynamic effects, etc.

This came after the firm presented a proposal for updating the prescribing information version 2, dated 24.04.2025 for the drug product Sodium Zirconium Cyclosilicate Powder for Oral Suspe

See Full Page